Introduction
Levodopa motor complications in Parkinson's disease

https://doi.org/10.1016/S1471-1931(00)00031-8Get rights and content

Parkinson's disease (PD) is an age-related neurodegenerative disorder with an average onset age of 60 years. In the United States, approximately one million persons suffer from PD, and there are 60 000 newly diagnosed cases every year. The estimated cost of PD to society is $27 billion per year. Based on United States Census Bureau projections, it is estimated that the frequency of PD will increase fourfold by the year 2040, making it an even larger burden on patients, their families and society.

Selected references (61)

  • OlanowC.W. et al.

    An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines (American Academy of Neurology)

    Neurology

    (1998)
  • JellingerK.

    The pathology of parkinsonism

  • KishS.J.

    Uneven pattern of dopamine loss in the striatum of patients with Parkinson's disease

    New Engl. J. Med.

    (1988)
  • VingerhoetsF.J.G.

    Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions

    Ann. Neurol.

    (1994)
  • CotziasG.C.

    Aromatic aminoacids and modification of parkinsonism

    New Engl. J. Med.

    (1967)
  • HughesA.J.

    Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

    J. Neurol. Neurosurg. Psychiatry

    (1992)
  • ObesoJ.A.

    Motor complications associated with chronic levodopa therapy in Parkinson's disease

    Neurology

    (1989)
  • FénelonG.

    Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors

    Brain

    (2000)
  • HughesT.A.

    A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease

    Neurology

    (2000)
  • RodriguezM.C.

    Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection

    Ann. Neurol.

    (1998)
  • OlanowC.W.

    Cell death and neuroprotection in Parkinson's disease

  • BenabidA.L.

    Subthalamic deep brain stimulation

    Prog. Neurolog. Surg.

    (2000)
  • Olanow, C.W. and Brin, M.F. Surgery for Parkinson's disease: a physician's perspective. Adv. Neurol. (in...
  • OlanowC.W. et al.

    Preventing levodopa-induced dyskinesias

    Ann. Neurol.

    (2000)
  • GrandasF.

    Risk factors for levodopa-induced dyskinesias in Parkinson's disease

    J. Neurol.

    (1999)
  • ColosimoC. et al.

    Motor fluctuations in Parkinson's disease: pathophysiology and treatment

    Eur. J. Neurol.

    (1999)
  • MarsdenC.D.

    Fluctuations of disability in Parkinson's disease: clinical aspects

  • FahnS.

    Fluctuations of disability in Parkinson's disease: pathophysiology

  • QuinnN.

    Young onset Parkinson's disease

    Mov. Disord.

    (1987)
  • LuquinM.R.

    Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification

    Mov. Disord.

    (1992)

    • Cited by (0)

    View full text
    Copyright © 2000 Published by Elsevier Ltd.